Exodus Point Capital Management, LP Albireo Pharma, Inc. Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$16.32 - $26.37 $277,945 - $449,107	-17,031 Reduced 32.19%	35,874 $695,000
Q2 2022 Aug 19, 2022	BUY	$18.54 - $37.29 $980,858 - $1.97 Million	52,905 New	52,905 $1.05 Million
Q1 2022 May 13, 2022	SELL	$23.94 - $33.74 $300,375 - $423,335	-12,547 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$21.19 - $31.29 $265,870 - $392,595	12,547 New	12,547 $292,000
Q3 2021 Nov 15, 2021	SELL	$27.36 - $35.98 $178,770 - $235,093	-6,534 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$28.9 - $36.87 $188,832 - $240,908	6,534 New	6,534 $230,000
Q4 2020 Feb 16, 2021	SELL	$31.56 - $42.16 $390,397 - $521,519	-12,370 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.19 - $41.61 $286,860 - $514,715	12,370 New	12,370 $413,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.